VHH single-chain anti-nucleolin antibodies fused to an Fc region of human IgG1 against melanoma cells showed greater ADCC activity than conventional VHH anti-nucleolin antibodies between 2 and 1.7 times. This evidence concerns the gene NUCLEOLIN and melanoma.